

IMMUNOGEN INC  
Form 8-K  
July 26, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **July 23, 2007**

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction of  
incorporation)

**0-17999**  
(Commission File Number)

**04-2726691**  
(IRS Employer Identification No.)

**128 Sidney Street, Cambridge, MA 02139**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

(a) Not applicable.

(b) On July 26, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) announced the July 23, 2007 resignation from the Company of Pauline Jen Ryan, formerly the Senior Vice President, Corporate Development and Operations.

A copy of the press release regarding Ms. Ryan's departure is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c), (d), and (e) Not applicable.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

Exhibit

No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated July 26, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: July 26, 2007

/s/ Daniel M. Junius  
Daniel M. Junius  
Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

Exhibit

No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated July 26, 2007

4

---